| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 614.29% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 11/17/2022 | 328.57% | Chardan Capital | $4 → $3 | Maintains | Buy |
| 08/12/2022 | 614.29% | SVB Leerink | $6 → $5 | Maintains | Outperform |
| 06/08/2022 | 1042.86% | Cantor Fitzgerald | $22 → $8 | Maintains | Overweight |
| 06/07/2022 | 757.14% | B. Riley Securities | $12 → $6 | Maintains | Buy |
| 06/07/2022 | 471.43% | Chardan Capital | $11 → $4 | Maintains | Buy |
| 06/07/2022 | 757.14% | SVB Leerink | $19 → $6 | Maintains | Outperform |
| 05/13/2022 | 1471.43% | Chardan Capital | $14 → $11 | Maintains | Buy |
| 05/13/2022 | 2614.29% | SVB Leerink | $20 → $19 | Maintains | Outperform |
| 03/30/2022 | 2757.14% | SVB Leerink | $24 → $20 | Maintains | Outperform |
| 03/30/2022 | 3900% | HC Wainwright & Co. | $25 → $28 | Maintains | Buy |
| 01/14/2022 | 3471.43% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/23/2021 | 3471.43% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 11/01/2021 | 3328.57% | SVB Leerink | → $24 | Initiates Coverage On | → Outperform |
| 09/13/2021 | 4185.71% | Laidlaw & Co. | → $30 | Initiates Coverage On | → Buy |
| 08/25/2021 | 3614.29% | B. Riley Securities | → $26 | Initiates Coverage On | → Buy |
| 08/13/2021 | 4185.71% | Chardan Capital | $33 → $30 | Maintains | Buy |
| 01/06/2021 | 4614.29% | Chardan Capital | → $33 | Initiates Coverage On | → Buy |
What is the target price for Vincerx Pharma (VINC)?
The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 614.29% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vincerx Pharma (VINC)?
The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Vincerx Pharma (VINC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
Is the Analyst Rating Vincerx Pharma (VINC) correct?
While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $0.70, which is within the analyst's predicted range.